Published Nov. 11, 2015
SCRA has made an investment in Kiyatec Inc., which operates alongside Greenville Health Systems Institute for Translational Oncology Research. SCRA’s Stage 2 program provides investments up to $5 million in South Carolina-based technology companies.
Kiyatec, started in 2005 by Matthew Gevaert and David Orr based on research Orr started at Clemson University, offers cell-based drug response profiling services for pharmaceutical and biotech companies using Kiyatec’s three-dimensional cell culture technology platform.
SCRA CEO Bill Mahoney said the Stage 2 program “uses retained earnings from SCRA’s core R&D operations to fulfill our mission to grow South Carolina’s high-tech landscape.”
“We have a long history with Kiyatec, first making an investment through our SC Launch program in 2008 and making several subsequent investments since,” Mahoney said.